Search
Close this search box.

Anti-glycan monoclonal antibodies: Basic research and clinical applications

Author(s)

K.M. Gillmann, J. S. Temme, S. Marglous, C.E. Brown & J. C. Gildersleeve

Sources

Current Opinion in Chemical Biology 2023, 74:102281 https://doi.org/10.1016/j.cbpa.2023.102281

Anti-glycan monoclonal antibodies have essential applications in human health and basic research. Therapeutic antibodies that recognize cancer- or pathogen-associated glycans have been investigated in numerous clinical trials, resulting in two FDA-approved biopharmaceuticals. Anti-glycan antibodies are also utilized to diagnose, prognosticate, and monitor disease progression, as well as to study the biological roles and expression of glycans.
897glycopedia.png
High-quality anti-glycan mAbs are still in limited supply, highlighting the need for new technologies for anti-glycan antibody discovery. This review discusses anti-glycan monoclonal antibodies with applications to basic research, diagnostics, and therapeutics, focusing on recent advances in mAbs targeting cancer- and infectious disease-associated glycans.
897_bis.png

Latest news

The role of glycosaminoglycans (GAGs) in modulating bone morphogenetic protein (BMP) signaling is a relatively...

Glycans, due to their variable compositions and highly dynamic conformations, significantly enhance the diversity of...

Advances in simulation, combined with technological developments in high-performance computing, have made it possible to...

Antimicrobial resistance (AMR) is one of the most critical threats to global public health in...